Sofidel America has decided to invest in Valmet's Advantage DCT tissue line including an extensive automation package, flow control valves and Industrial Internet solutions to its Circleville mill in Ohio, United States. The start-up is scheduled for the second half of 2025. The value of the order will not be disclosed.
Valmet and Sofidel share a long history of partnership including eleven conventional tissue machines and four hybrid machines installed in various countries. The new Advantage DCT 200 (TM 3) line follows the two Valmet Advantage NTT lines installed at the Circleville mill in 2017.
The new tissue line will have a design speed of 2,000 m/min and a width of 5,6 meters. The production line is optimized to save energy and deliver excellent paper properties. The line will have an annual production capacity of 70,000 tons.
Valmet's scope of supply comprises a complete tissue production line including Advantage DCT 200 tissue machine with OptiFlo headbox and Yankee cylinder. It will also be featured with the Advantage tissue technology including ViscoNip press, AirCap hood with Air system, WetDust systems and a SoftReel reel. Valmet has also delivered detailed mill engineering, stock preparation equipment as well as automation, including Valmet DNA Distributed Control System (DCS) with built-in machine condition monitoring, Valmet IQ Quality Control System (QCS) and Web Monitoring System (WMS). The delivery also includes Valmet's flow control and Industrial Internet solutions including Valmet Performance Center services, and Valmet Quality Predictor and Centerline Advisor applications.
The Sofidel Group, a privately held company, is one of the leading manufacturers of paper for hygienic and domestic use worldwide. Sofidel America is a subsidiary of the Sofidel Group. It was established in 2012 through the acquisition of the Cellynne tissue company.
Valmet is a leading global developer and supplier of process technologies, automation and services for the pulp, paper and energy industries.